康努西德通过促进线粒细胞衰变通过减弱NLRP3介导的神经毒性来缓解由Aβ1-42诱导的认知障碍
Fulin Zhou1, Wenwen Lian1, Xiaotang Yuan2
1Institute of Clinical Medical Sciences, Department of Pharmacy, China-Japan, Friendship Hospital 2nd, Yinghua Dongjie, Chaoyang District, Beijing, 100029, People's Republic of China.
Alzheimer's research & therapy
|February 19, 2025
概括
康努西德是Cornus officinalis中的一种化合物,通过增强线粒细胞吸收来清除受损的线粒体来对抗阿尔茨海默病. 这一过程抑制神经炎症,保护神经元,并在小鼠模型中改善认知功能.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 细胞生物学 细胞生物学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特征是线粒体功能障碍和神经炎症.
- 来自Cornus officinalis的Cornuside已经显示出作为抗AD剂的潜力,但其作用机制尚未完全理解.
研究的目的:
- 为了阐明在阿尔茨海默病中角质的潜在神经保护机制.
- 为了研究NLRP3炎症酶激活和线粒细胞衰减在康努西德治疗效果中的作用.
主要方法:
- 阿尔茨海默病的小鼠模型是通过Aβ1-42脑内静脉注射诱导的,并用不同剂量的cornuside治疗.
- 在体外研究中使用暴露于LPS和Aβ1-42的BV2细胞来评估NLRP3炎症和线粒细胞衰变途径.
- 分析了线粒体功能,线粒体的标志物 (LC3B,SQSTM1/p62,Pink1/Parkin),NLRP3炎症组分和神经元损伤.
主要成果:
- 在AD小鼠中,Cornuside治疗显著改善了认知缺陷,突触可塑性和神经元存活率.
- 康努赛德抑制了NLRP3炎症酶激活,并促进了线粒,通过减少炎症标记物和通过Pink1/Parkin通路增强自流来表明.
- 在实验室中,角化保护了神经元,改善了线粒体功能 (氧化酸化,糖解),减少了ROS,并抑制了NLRP3炎症酶激活. 使用3-MA阻断线粒会消除这些保护作用.
结论:
- 康努西德恢复了线粒体流,清除受损的线粒体并恢复线粒体功能,这对于抑制NLRP3炎症酶激活至关重要.
- 角酸的神经保护作用包括促进线粒,从而减少神经炎症,改善神经元和突触完整性.
- 康纳赛德通过向线粒体健康和神经炎症途径,证明了阿尔茨海默病的显著治疗潜力.
相关概念视频
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429


